GL-ONC1
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Organ Cancers
Conditions
Solid Organ Cancers
Trial Timeline
Mar 25, 2016 → Aug 6, 2019
NCT ID
NCT02714374About GL-ONC1
GL-ONC1 is a phase 1 stage product being developed by Genelux for Solid Organ Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT02714374. Target conditions include Solid Organ Cancers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03420430 | Pre-clinical | Completed |
| NCT02714374 | Phase 1 | Terminated |
| NCT01766739 | Phase 1 | Completed |
| NCT01584284 | Phase 1 | Completed |
| NCT01443260 | Phase 1/2 | Completed |
| NCT00794131 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Organ Cancers
Other Products from Genelux
olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)Phase 3
69
Olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin or cisplatin + Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC + Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab + DocetaxelPhase 2
44
GL-ONC1Phase 1/2
33
Olvi-Vec + platinum (cisplatin or carboplatin) + EtoposidePhase 1/2
33
GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumabPhase 1/2
33